{"name":"IDEAYA Biosciences","slug":"ideaya-biosciences","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"IDE-161","genericName":"IDE-161","slug":"ide-161","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"IDE196","genericName":"IDE196","slug":"ide196","indication":"Non-small cell lung cancer","status":"phase_2"}]}],"pipeline":[{"name":"IDE-161","genericName":"IDE-161","slug":"ide-161","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"IDE196","genericName":"IDE196","slug":"ide196","phase":"phase_2","mechanism":"Selective inhibitor of MEK1/2","indications":["Non-small cell lung cancer","Colorectal cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxNWjczTHRrN09LaS1ORW1Mb09CSkR6dEREWVp6UGgxbDNSVDkzdnBTSjR4WXB4VHJyUG9jS0lZTnBpX0FZNUR3MEFlN3JIckNtOXJMZVNtdVBDR0lWdVE1UEk5Zk5qek9zX0djUGR5Ym5oYmJBMDlVRnhuajh5REk1SmhBaXNaamo0SEFDQTlNZzJ4RmZseTVGZWxRSDg2QzBYTVcxbXI4emFpV0lUOUtQbzB0M05MdkEzMURUTmRMU1VZY1JSRDE1MW1qWS1uMTBONzdjRENzWFB6Y0dqLXVibHR2SG4?oc=5","date":"2026-04-07","type":"trial","source":"BioPharma APAC","summary":"IDEAYA Biosciences Advances IDE574 Into Phase 1 As First Patient Enrolled For KAT6 And KAT7 Dual Inhibitor - BioPharma APAC","headline":"IDEAYA Biosciences Advances IDE574 Into Phase 1 As First Patient Enrolled For KAT6 And KAT7 Dual Inhibitor","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNZDRZQ1RpdzVsOVZOdDB4V0F2QjlKaTB4VnJWczVVUTh2NkpLYVM0aFprMHJMYlRkYVhQLVIyYWJtNDN5b2JtOHNXc3NJdTJGUDYtamh4alZMV0VHbzc1UGtoYllBalAtODh4MFJSQ0pHdkdBcVF0VjdrWVd2c09taTRfbVZ2VEwyQWktclVQLWlZTXlLTDk3OFRObzBJT0Jnek9DOUpUekNHa1VEY2VBeC1pUQ?oc=5","date":"2026-04-02","type":"pipeline","source":"AD HOC NEWS","summary":"Ideaya Biosciences Stock: Can This Oncology Bet Keep Running? - AD HOC NEWS","headline":"Ideaya Biosciences Stock: Can This Oncology Bet Keep Running?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPQWRnOU1udGdVTjVwSzlxTTgxRFk3Sm5uUWZWd2Q3T28xQURmUUlGaXBjN2Rsc0lQTlJoamR1NzQ0czRKdUhFM3dDUlRpaXJsX1gxeThQNE5oLU1nUWVkOUNSSzc5c090MWcxS2ZjR0JyOEVtWUxScFpmTFJuUEE1ODFHc1RrTzByNTNhcjNwOGNfZU0?oc=5","date":"2025-12-09","type":"pipeline","source":"The Pharma Letter","summary":"GSK ends synthetic lethality pact with Ideaya - The Pharma Letter","headline":"GSK ends synthetic lethality pact with Ideaya","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPSjJWV0F4Wmp3VVJvclBwaF82azBobzIwNFlwTXByX1hpaWxUY1pnV09XVHItYmdmX1I4MzYxZnJBOFZqRXdKdWxaXzhnQmNYSm9taEpJa0hudXZXS3FPNXBna2xXTmZCVnVzalBlUnBEMGtIeEdSWDVRVG5zTDZnY2p2cDNLWEpEdkNzc1dkaVltOHM?oc=5","date":"2025-12-08","type":"deal","source":"BioSpace","summary":"GSK Cuts Five-Year-Old Cancer Collaboration With Ideaya - BioSpace","headline":"GSK Cuts Five-Year-Old Cancer Collaboration With Ideaya","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTFB1eF9qMzZidGJRR1R3WmdOQUF4clpvME1oZGtEWGdBMlk4aTgwQkV6TGRrdHltQlBaY2hscXlGdHVTSUttaHlUNklxMjE0RWRSUVo5dTRlQzJWTDJVcGh0d0ctRjUyTXJSbjkyQnBWbEw4NFlaWGsxVA?oc=5","date":"2025-12-08","type":"regulatory","source":"Endpoints News","summary":"GSK walks away from remaining Ideaya programs, formally ending partnership - Endpoints News","headline":"GSK walks away from remaining Ideaya programs, formally ending partnership","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAJBVV95cUxQT195Um84VEw5TDFnZ0x5N0VydUJ0aDNTVGF1SDVWdjh0bEFwbEtyZzM4R2ZEbENDdTVwQzJSV0ZrUU9JSlVZbTZ5TXlYd3NyYmpXT3pVMzdEUHRuTi1lYURucmpkR2M4bzJTeTFNU05iM3dIX0JNNzdoT1otUWVoT3VZamZrTzA5bmYxaUxmTEMxZVpuWm5aRFlVdmZWeXRxU2lWclBRLXg0eEZndGl6VkxBUGRYWjFHdHp0bU9jdnQ1SmpfLXlOd3dPTkhSMTJPRHdDZlpfMjdHQjNyR21Zd2pnU21aQTNOam1SZUw5ZkNyb19xOUMyc0pxRnl4Z2hnRHdLc19CTkdQSy1EYTdDTFRuYkZYRHE0S2tFYm1TMVI?oc=5","date":"2025-10-14","type":"trial","source":"GlobeNewswire","summary":"Melanoma Clinical Trial Pipeline Accelerates as 150+ Pharma - GlobeNewswire","headline":"Melanoma Clinical Trial Pipeline Accelerates as 150+ Pharma","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-09-07","type":"trial","source":"prnewswire.com","summary":"IDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the IASLC 2025 World Conference on Lun","headline":"IDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DL","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBTemozczIxZFRyaW1vSmJEM0hKSElLQ2JtWm9OQlFnRFA0Vm5GSFFxMmtKYVRRN3JuaWt5b0E0Um1Xd25lRW9mZDlvV3pTamhqM1RJ?oc=5","date":"2025-09-02","type":"deal","source":"FirstWord Pharma","summary":"Servier pockets ex-US rights to IDEAYA’s eye cancer drug in $530M deal - FirstWord Pharma","headline":"Servier pockets ex-US rights to IDEAYA’s eye cancer drug in $530M deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxOTGx0YlJlT2VDWk85Y3doVkVDd09VTF92WDVGdkxrY3VQamwxd01JUnFWaDZVWFJmSnhNYWlTOFJpRms4QnNETzV4a21IT2xwT1pfa3dtc1k5SzFEN1NQcDhkam0xTUppWkdsSzV6bXN0ZTRvNzFkUWc3ODgxa3FTSFhaS21fTU0?oc=5","date":"2025-09-02","type":"pipeline","source":"Servier","summary":"Promising Uveal Melanoma Treatment - Servier","headline":"Promising Uveal Melanoma Treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxPVmZQR0h3eHBoRmQ5QkRTSXg3U3Q4dUEzMEVIcFhHVUhxaDNDMFdSX0F1Z2J4VDB4WXZLWFZQV1pVb3VUODJZWlBBWXlzZ01uZjk0VWI0TER1QXBNdXpqc0VYWTF5R2RON3phSlRZVTJIX3pid2U5SlN0eUxRVFBxVUxsekNqX2h6Q19EcHJCcnY4Z3R4NzNPWnBkSmtZb0ZCX2RhWTRTMU5FWXd5ZkFLUEhfRGJVWjNXMVRFYXNWU1BFcEpYdWJtdA?oc=5","date":"2025-09-02","type":"deal","source":"fiercebiotech.com","summary":"Servier shells out $210M upfront to license Ideaya's potential first-in-class PKC inhibitor outside the US - fiercebiotech.com","headline":"Servier shells out $210M upfront to license Ideaya's potential first-in-class PKC inhibitor outside the US","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxOUlBwZG9QOUVDWlZ3MFRWZ0tHQVJVN0RVLTY1THg1clFHS04wbTRVaXRHaDBHZkthSUw1Zmd2MUVJZkp1ZTEzSi0wMXk1SGFaTEF0SHBIa0NOdlJoVFBPbDUxWFhXSXZ3SW1DQmdETXBHQ0F6R0c3bzNSREZha192TUlVWkNZd2pBMTF6azNRNGJxZHpQakVoUXVIMEtvMlBqaEdTeWQ5dmtXeWhrNHFWa2wtRFlGYzlOQVIzOVp3eW51NTVweGdrVDFFYWd0LVd3VWlWbkdJMlY1ak9GMUNLa2VvajU4YmNIb3E3NUszY0VGQVZvNi1KWi1QcWZwajdJa1RyZDln?oc=5","date":"2025-09-02","type":"deal","source":"prnewswire.com","summary":"Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide - prnewswire.com","headline":"Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwid","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNYnl0WVF5RnRlUWZHeHNwUUZ4UmZlTGdkRkVjNVh6VFV4RnlROEdqVDRUdENaa3E4dlU4TWI1N0ZvQzZIc0E1dU9VRlAxOVFneHBWM3pUTDdfQTRNeDVaQm9Yd2FFVVhha3VuMDcwNmVnRUhJUUh6TTl6N2JiY2pLdEJNeVJGRThQMjNENGZfUnR4cnluLUpVNQ?oc=5","date":"2024-11-19","type":"pipeline","source":"Fierce Pharma","summary":"Ideaya hires Gilead leader to head up commercialization push - Fierce Pharma","headline":"Ideaya hires Gilead leader to head up commercialization push","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":1,"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}